First ‘living medicine’ that treats antibiotic-resistant bacteria developed by scientists

New treatment targets infections on medical implants such as prosthetic joints, catheters and pacemakers

Tom Batchelor
Thursday 07 October 2021 11:25
Comments
<p>An illustration of antibiotic resistant bacteria inside a biofilm, which the new treatment specifically targets </p>

An illustration of antibiotic resistant bacteria inside a biofilm, which the new treatment specifically targets

Researchers in Spain have created the world’s first “living medicine” to treat antibiotic-resistant bacteria growing on the surfaces of medical implants.

The team at Barcelona’s Centre for Genomic Regulation and Pulmobiotics created the treatment by removing a common bacteria’s ability to cause disease and repurposing it to attack harmful microbes instead.

Injecting the therapy under the skin of mice treated infections in 82 per cent of the treated animals, the study found.

Developing bacteria that is resistant to antibiotics would provide a major step forward in the development of treatments for infections on medical implants such as prosthetic joints, catheters and pacemakers, which are highly resistant to antibiotics and account for around four in five of all infections acquired in hospital settings.

The new treatment specifically targets biofilms, which are colonies of bacterial cells that stick together on a surface, forming impenetrable structures that prevent antibiotics or the human immune system from destroying them.

Medical implants provide the ideal growing conditions for biofilms, and biofilm-associated bacteria can be a thousand times more resistant to antibiotics than free-floating bacteria.

One of the most common species of biofilm-associated bacteria, Staphylococcus aureus, does not respond to conventional antibiotics, leaving patients needing surgery to remove any infected medical implants.

Alternative treatments such as the use of antibodies or enzymes are highly toxic for normal tissues and cells and can cause unpleasant side effects.

The authors of the study set about investigating whether directly producing enzymes near to biofilms would be a safer and cheaper way of treating infections.

Wokring with Mycoplasma pneumoniae, a common species of bacteria, it was first modified so that it would not cause illness before further tweaks made it produce two different enzymes that dissolve biofilms and attack the cell walls of the bacteria embedded within.

María Lluch, co-author of the study and chief science officer of Pulmobiotics, said: “Our technology, based on synthetic biology and live biotherapeutics, has been designed to meet all safety and efficacy standards for application in the lung, with respiratory diseases being one of the first targets. Our next challenge is to address high-scale production and manufacturing, and we expect to start clinical trials in 2023.”

Luis Serrano, director of the Centre for Genomic Regulation and co-author of the study, said: “Bacteria are ideal vehicles for ‘living medicine’ because they can carry any given therapeutic protein to treat the source of a disease.

“One of the great benefits of the technology is that once they reach their destination, bacterial vectors offer continuous and localised production of the therapeutic molecule.

“Like any vehicle, our bacteria can be modified with different payloads that target different diseases, with potentially more applications in the future.”

The study is published in the journal Molecular Systems Biology.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in